{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:27:29Z","timestamp":1791851249508,"version":"4.3.4"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":33,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>\n                    Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon\u2010free, all\u2010oral combinations of direct\u2010acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions. In this report, we discuss the viral proteins targeted by HCV direct\u2010acting antivirals and summarize clinically relevant resistance data for compounds that have been approved or are currently in phase 3 clinical trials.\n                    <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                    : This report provides a comprehensive, systematic review of all resistance information available from sponsors\u2019 trials as a tool to inform the HCV drug development field. (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2015;62:1623\u20131632)\n                  <\/jats:p>","DOI":"10.1002\/hep.27934","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T10:55:12Z","timestamp":1434711312000},"page":"1623-1632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":258,"title":["Hepatitis C virus drug resistance\u2013associated substitutions: State of the art summary"],"prefix":"10.1097","volume":"62","author":[{"given":"Erik","family":"Lontok","sequence":"first","affiliation":[{"name":"Forum for Collaborative HIV Research, University of California at Berkeley,Washington,DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Harrington","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration,Silver Spring,MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Howe","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories,West Point,PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Kieffer","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals, Inc.,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lennerstrand","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences,Uppsala University,Uppsala,Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[{"name":"Janssen Infectious Diseases,Beerse,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Research and Development,Wallingford,CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.,Foster City,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parkin","sequence":"additional","affiliation":[{"name":"Data First Consulting, Inc.,Belmont,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Pilot\u2010Matias","sequence":"additional","affiliation":[{"name":"AbbVie, Inc.,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[{"name":"Forum for Collaborative HIV Research, University of California at Berkeley,Washington,DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"hep27934-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2013the arc of a medical triumph","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon\u2010alpha therapy","volume":"282","year":"1998","journal-title":"Science"},{"key":"hep27934-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/jvi.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase","volume":"69","year":"1995","journal-title":"J Virol"},{"key":"hep27934-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"hep27934-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/clpt.2014.113","article-title":"Accelerating drug development through collaboration: the hepatitis C drug development advisory group","volume":"96","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"hep27934-bib-0006-20241017","first-page":"10","article-title":"Clinically Relevant HCV Drug Resistance Mutations Fig. and Tables","volume":"14","year":"2012","journal-title":"Ann Forum Collab HIV Res"},{"key":"hep27934-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","year":"2013","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"hep27934-bib-0010-20241017","first-page":"85","article-title":"New therapeutic strategies in HCV: polymerase inhibitors","volume":"33","year":"2013","journal-title":"Liver Int"},{"key":"hep27934-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS\u2010790052 in an in vitro replicon system","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","article-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","volume":"3","year":"2013","journal-title":"Curr Opin Virol"},{"key":"hep27934-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment\u2010naive patients","volume":"9","year":"2012","journal-title":"Virol J"},{"key":"hep27934-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1053\/j.gastro.2011.01.029","article-title":"Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG","volume":"140","year":"2011","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","year":"2006","journal-title":"Antiviral Res"},{"key":"hep27934-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment\u2010naive and treatment\u2010experienced patients receiving telaprevir\u2010based therapy in clinical trials","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"hep27934-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","article-title":"In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1128\/AAC.00677-09","article-title":"MK\u20107009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI\u20107977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","year":"2010","journal-title":"Nature"},{"key":"hep27934-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.02495-13","article-title":"Preclinical characterization of BMS\u2010791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","year":"2012","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"hep27934-bib-0029-20241017","first-page":"69","article-title":"HCV direct\u2010acting antiviral agents: the best interferon\u2010free combinations","volume":"34","year":"2014","journal-title":"Liver Int"},{"key":"hep27934-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"hep27934-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1136\/gutjnl-2012-302144","article-title":"New direct\u2010acting antiviral agents for the treatment of hepatitis C virus infection and perspectives","volume":"61","year":"2012","journal-title":"Gut"},{"key":"hep27934-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment\u2010emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","year":"2013","journal-title":"Clin Infect Dis"},{"key":"hep27934-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment\u2010naive patients with chronic hepatitis C virus genotype 1 infection (QUEST\u20101): a phase 3, randomised, double\u2010blind, placebo\u2010controlled trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"hep27934-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment\u2010naive patients with chronic hepatitis C virus genotype 1 infection (QUEST\u20102): a randomised, double\u2010blind, placebo\u2010controlled phase 3 trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"hep27934-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non\u2010responders to pegylated interferon and ribavirin and treatment\u2010naive patients: the COSMOS randomised study","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"hep27934-bib-0038-20241017","article-title":"Virology analyses of HCV isolates from genotype 1\u2010infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","year":"2014","journal-title":"J Hepatol"},{"key":"hep27934-bib-0040-20241017","article-title":"All\u2010oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","year":"2014","journal-title":"Lancet"},{"key":"hep27934-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep27934-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon\u2010 and ribavirin\u2010free regimen of daclatasvir, asunaprevir, and BMS\u2010791325 in treatment\u2010naive patients with HCV genotype 1 infection","volume":"146","year":"2014","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jhep.2014.07.011","article-title":"Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep27934-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT\u2010450\/r\u2010ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT\u2010450\/r\u2010ombitasvir and dasabuvir with ribavirin","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT\u2010450\/r\u2010ombitasvir and dasabuvir with ribavirin","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0049-20241017","first-page":"1146A","article-title":"Identification and treatment of multiple subtypes of HCV genotype 4 in the PEARL\u2010I study with ombitasvir and ABT\u2010450\/r\u2009\u00b1\u2009ribavirin","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"hep27934-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.virol.2013.05.013","article-title":"Emergence of resistance\u2010associated variants after failed triple therapy with vaniprevir in treatment\u2010experienced non\u2010cirrhotic patients with hepatitis C\u2010genotype 1 infection: a population and clonal analysis","volume":"443","year":"2013","journal-title":"Virology"},{"key":"hep27934-bib-0051-20241017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","article-title":"Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics","volume":"99","year":"2013","journal-title":"Antiviral Res"},{"key":"hep27934-bib-0052-20241017","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","year":"2014","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0053-20241017","article-title":"Daclatasvir\u2010Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus\u2010Induced Membranous Replication Factories, Independent of RNA Replication","year":"2014","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0054-20241017","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS\u2010790052 in humans: in vitro and in vivo correlations","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep27934-bib-0055-20241017","article-title":"Daclatasvir plus Peginterferon and Ribavirin is Non\u2010inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection","year":"2014","journal-title":"Gastroenterology"},{"key":"hep27934-bib-0056-20241017","article-title":"Exploratory trial of ombitasvir and ABT\u2010450\/r with or without ribavirin for HCV genotype 1, 2, and 3 infection","year":"2014","journal-title":"J Infect"},{"key":"hep27934-bib-0059-20241017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All\u2010oral 12\u2010week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY\u20103 phase III study","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep27934-bib-0060-20241017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo\u2010controlled, 3\u2010day, dose\u2010ranging study of GS\u20105885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep27934-bib-0061-20241017","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple\u2010dose clinical trial of the novel NS5A inhibitor GS\u20105885","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"hep27934-bib-0062-20241017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0063-20241017","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1128\/jb.177.22.6321-6329.1995","article-title":"Polymerase structures and function: variations on a theme?","volume":"177","year":"1995","journal-title":"J Bacteriol"},{"key":"hep27934-bib-0064-20241017","first-page":"1","article-title":"GS\u20109669: a novel non\u2010nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"hep27934-bib-0065-20241017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0066-20241017","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27934-bib-0067-20241017","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for Sofosbuvir","year":"2014","journal-title":"Hepatology"},{"key":"hep27934-bib-0068-20241017","article-title":"Infrequent Development of Resistance in Genotype 1\u20106 Hepatitis C Virus\u2010Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials","year":"2014","journal-title":"Clin Infect Dis"},{"key":"hep27934-bib-0069-20241017","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/AAC.02579-13","article-title":"Randomized, Placebo\u2010Controlled, Single\u2010Ascending\u2010Dose Study of BMS\u2010791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection","volume":"58","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"hep27934-bib-0070-20241017","first-page":"S33","article-title":"Antiviral resistance and the future landscape of hepatitis C virus infection therapy","volume":"207","year":"2013","journal-title":"J Infect Dis"},{"key":"hep27934-bib-0071-20241017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct\u2010acting antiviral agents","volume":"108","year":"2014","journal-title":"Antiviral Res"},{"key":"hep27934-bib-0072-20241017","article-title":"Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV\u2010TARGET","year":"2014","journal-title":"J Hepatol"},{"key":"hep27934-bib-0073-20241017","first-page":"A20","article-title":"Clinical resistance to NS5A inhibitors: virologic escape and long\u2010term persistence","volume":"19","year":"2014","journal-title":"Antiviral Therapy"},{"issue":"Suppl S1","key":"hep27934-bib-0076-20241017","first-page":"59","article-title":"JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1","volume":"44","year":"2014","journal-title":"Hepatol Res"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27934","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201511000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:18:38Z","timestamp":1729196318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201511000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27934","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725579792.793507854","asserted-by":"object"}]},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]},"assertion":[{"value":"2014-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}